Australia Onychomycosis Market Size & Outlook, 2023-2030
Australia onychomycosis market, 2018-2030 (US$M)
Related Markets
Australia onychomycosis market highlights
- The Australia onychomycosis market generated a revenue of USD 56.1 million in 2023 and is expected to reach USD 87.7 million by 2030.
- The Australia market is expected to grow at a CAGR of 6.6% from 2024 to 2030.
- In terms of segment, topical was the largest revenue generating treatment in 2023.
- Topical is the most lucrative treatment segment registering the fastest growth during the forecast period.
Onychomycosis market data book summary
| Market revenue in 2023 | USD 56.1 million |
| Market revenue in 2030 | USD 87.7 million |
| Growth rate | 6.6% (CAGR from 2023 to 2030) |
| Largest segment | Topical |
| Fastest growing segment | Topical |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Oral, Topical |
| Key market players worldwide | GSK PLC, Abbott Laboratories, Pfizer Inc, Bausch Health Companies Inc, Bayer AG, Teva Pharmaceutical Industries Ltd, Cipla Ltd DR, Merck & Co Inc, Novartis AG ADR, Sun Pharmaceutical Industries |
Other key industry trends
- In terms of revenue, Australia accounted for 1.6% of the global onychomycosis market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China onychomycosis market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 374.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Onychomycosis Market Scope
Onychomycosis Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Australia onychomycosis market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to onychomycosis market will help companies and investors design strategic landscapes.
Topical was the largest segment with a revenue share of 57.75% in 2023. Horizon Databook has segmented the Australia onychomycosis market based on oral, topical covering the revenue growth of each sub-segment from 2018 to 2030.
The onychomycosis market in Australia is expected to significantly grow owing to the rising prevalence of target diseases such as diabetes and the growing geriatric population across the country.
The country is expected to witness a significant increase in onychomycosis patients due to the high prevalence of diabetes. According to a report published by the Australian Institute of Health and Welfare in December 2023, over 1.3 million Australians were suffering from diabetes in the country in 2021.
In addition, according to an article published by the Australian Research Council (ARC) Centre of Excellence in Population Ageing Research (CEPAR), the country’s population aged 65 and over is projected to increase to 6.66 million by 2041 from an estimated 4.31 million in 2021.
Reasons to subscribe to Australia onychomycosis market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia onychomycosis market databook
-
Our clientele includes a mix of onychomycosis market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia onychomycosis market , including forecasts for subscribers. This country databook contains high-level insights into Australia onychomycosis market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Australia onychomycosis market size, by treatment, 2018-2030 (US$M)
Australia Onychomycosis Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
